Gastric neuroendocrine neoplasms and proton pump inhibitors: Fact or coincidence?

Federica Cavalcoli, Alessandra Zilli, Dario Conte, Clorinda Ciafardini, Sara Massironi

Research output: Contribution to journalArticlepeer-review


Objective. Reporting on three cases of gastric neuroendocrine tumors (g-NETs) in patients taking long-term proton pump inhibitors (PPIs). These tumors are not classifiable considering current criteria. g-NETs are currently grouped as: types 1 and 2, related to hypergastrinemia due to chronic atrophic gastritis and Zollinger-Ellison syndrome respectively, and type 3, normogastrinemic and more aggressive. Although the g-NETs onset in patients taking PPIs is biologically plausible, only a few cases have been reported so far. Materials and methods. From January 2005 to July 2014, 31 g-NETs were referred to our Unit: 24 (77%), one (3%) and three (10%) resulted types 1, 2 and 3, respectively. Three cases (10%) did not meet the current classification criteria. Results. The three patients were administered long-term PPIs for gastro-esophageal reflux disease. Patient 1: a 78-year-old man, with a 4-mm well-differentiated g-NET (Ki-67

Original languageEnglish
Pages (from-to)1397-1403
Number of pages7
JournalScandinavian Journal of Gastroenterology
Issue number11
Publication statusPublished - 2015


  • Chronic atrophic gastritis
  • Classification system
  • Gastric neuroendocrine tumors
  • Gastrin
  • Proton pump inhibitor
  • Zollinger-Ellison syndrome

ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'Gastric neuroendocrine neoplasms and proton pump inhibitors: Fact or coincidence?'. Together they form a unique fingerprint.

Cite this